Mark N Stein, MD

Assistant Professor, Medicine, RWJMS The Cancer Institute of New Jersey 195 Little Albany Street New Brunswick, NJ 08093

Clinical Specialty: Prostate Cancer, Testis Cancer, Bladder Cancer, and Phase I Clinical Trials

Degree

• Fellowship from Mount Sinai School of Medicine
• Internship from Montefiore Medical Center, Albert Einstein College of Medicine
• MD from New York Medical College
• BS from Yale University

Honors

• Robert DiPaola Research Award
  Gallo Center (2008)

Society

• American Society of Hematology (2005 - Present)
• SRB (Scient Review Board) (2006 - Present)
• ASCO (2009 - Present)

Publications

• Stein, M.N., White, E., DiPaola, RS, Targeted Approaches to the Treatment of Prostate Cancer at Cancer Insitute of New Jersey. Urology, 2009. 20095;
• Dreicer, R., Li, H., Stein, M., DiPaola, R., Eleff, M., Roth, B.J., and Wilding, G., Phase II Trial of Sorafenib in Patients with Advanced Urotheilial Cancer; ECOG. 2009; 115:4090-5.
• Shao, Y.H., Demissie, K., Shih, W., Mehta, A.R. Stein, M.N., Roberts, C.B., Dipaola, R.S., and Lu-Yao, G.L., " Contemporary risk profile of prostate cancer in the United States. NCI . 2009; 101:1280-1283.

Research

• Clinical Trial - A Phase I Dose Escalation Trial Of 20 Deoxy-D-glucose (2DG) Alone and in Combination with Docetaxal in Subjects with Advanced Solid Malignancies
• Clinical Trial- An Open-Label, Dose Escalation Phase I/II Trial of a KSP Inhibitor Given as a Constant 24 Hour Infusion in Patients with Advanced Solid Tumors